查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1941884

病毒載體市場規模、佔有率和趨勢分析報告：按載體類型、應用、最終用途、地區和細分市場預測（2026-2033 年）

Viral Vector Market Size, Share & Trends Analysis Report By Vector Type (AAV, Adenovirus, Lentivirus, Retrovirus), By Application (Cell & Gene Therapy, Vaccine), By End Use, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10個工作天內

價格

病毒載體市場概述

2025年全球病毒載體市場規模估計為42.5億美元，預計2033年將達到102.2億美元。

預計從 2026 年到 2033 年，該市場將以 11.69% 的複合年成長率成長。目標疾病和遺傳性疾病的日益普遍，以及數位診斷技術的進步，預計將支持病毒載體市場的成長。

此外，病毒載體在基因治療中療效的提升也促進了市場成長。遺傳疾病和感染疾病的不斷增加預計將推動對病毒載體的需求成長。例如，根據聯合國愛滋病規劃署（UNAIDS）的數據，到2024年，全球將有約4,080萬人感染愛滋病毒。這種情況正在推動市場成長。此外，政府主導的各項舉措，例如直接增加對創新臨床療法的需求、為病毒載體生產提供資金，以及對新興的遺傳疾病治療領域日益成長的關注（該領域正透過技術主導取得進展），都在推動市場擴張。

在基因和細胞療法研發、疫苗創新以及先進生物製藥製造的強勁發展勢頭推動下，市場持續快速擴張。在這個市場環境下，隨著越來越多的治療方法從臨床試驗走向商業化，病毒載體製造和生產市場需求持續旺盛，對擴充性的、符合GMP規範的生產能力提出了更高的要求。同時，病毒載體和質體DNA製造市場的策略重要性日益凸顯，因為質體DNA是病毒載體生產的關鍵原料，直接影響產量、品質和生產進度。此外，儘管病毒載體在臨床研發管線中仍佔據主導地位，但由於人們對具有安全性、可重複性和易於生產等優勢的替代遞送技術的興趣日益濃厚，非病毒載體行業正逐漸成為一個補充領域。

從經營模式角度來看，病毒載體CDMO市場是產業成長的核心支柱，因為生物製藥公司擴大將研發和生產外包給專業合作夥伴，以降低資本風險並縮短產品上市時間。 CDMO公司正在擴展其能力，以處理多種載體類型，並提供整合質體DNA供應、上游工程和下游加工以及分析服務的端到端解決方案。此外，病毒載體疫苗市場持續推動整體需求，這得益於近期全球健康舉措中平台有效性的檢驗以及感染疾病和腫瘤疫苗的持續研發。這些相互關聯的細分市場共同構成了一個充滿活力且資本密集的市場，而擴大產能、技術創新和策略合作對於長期成長仍然至關重要。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章 市場變數、趨勢與範圍

  • 市場區隔和範圍
  • 市場體系展望
    • 母市場展望
    • 相關及補貼市場展望
  • 市場趨勢與展望
  • 市場動態
  • 市場限制因素分析
    • 複雜的製造流程。
    • 監管挑戰和智慧財產權問題。
  • 商業環境分析
    • SWOT分析；以因素（政治/監管、經濟、技術）進行分析
    • 波特五力分析

第4章：病毒載體市場：依載體類型分類的市場規模估算與趨勢分析

  • 病毒載體市場：按載體類型分類的波動分析
  • 腺結合病毒（AAV）
  • 腺病毒
  • 慢病毒
  • 逆轉錄病毒
  • 其他

第5章：病毒載體市場：按應用分類的規模估算與趨勢分析

  • 病毒載體市場：基於應用的波動分析
  • 細胞和基因治療
  • 疫苗
  • 生物製藥和藥物研發

第6章：病毒載體市場：依最終用途分類的市場規模估算與趨勢分析

  • 病毒載體市場：終端用途波動分析
  • 製藥和生物技術公司
  • 學術和研究機構
  • 合約研究組織 (CRO) 和合約行銷組織 (CMO)

第7章：病毒載體市場：區域規模估算與趨勢分析

  • 病毒載體的區域市場佔有率（2025 年和 2033 年）
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲

第8章 競爭情勢

  • 公司分類
  • 策略規劃
  • 公司簡介/列表
    • Oxford Biomedica
    • Thermo Fisher Scientific, Inc.
    • Lonza.
    • Batavia Biosciences BV
    • Biogen
    • Asklepios BioPharmaceutical, Inc.（AskBio）
    • Sanofi
    • Spark Therapeutics, Inc.
    • Regenxbio Inc.
    • uniQURE NV
Product Code: GVR-4-68040-072-3

Viral Vector Market Summary

The global viral vector market size was estimated at USD 4.25 billion in 2025 and is projected to reach USD 10.22 billion by 2033, growing at a CAGR of 11.69% from 2026 to 2033. The increasing prevalence of target diseases and genetic disorders, along with technological advancements in digital diagnostics, is expected to support the market growth for viral vectors.

Furthermore, increasing the effectiveness of viral vectors in gene therapy delivery is contributing to the market growth. The rising prevalence of genetic disorders and contagious diseases is anticipated to boost the demand for viral vectors. For instance, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS) data, around 40.8 million people were living with HIV in 2024. This is fueling market growth. Furthermore, government initiatives such as direct growing demand for innovative clinical therapies, funding for viral vector manufacturing, and an increasing focus on the emerging area of medicine for genetic disorders, which has been helped by transforming techniques, are driving market expansion.

The market continues to expand rapidly, underpinned by strong momentum in gene and cell therapy development, vaccine innovation, and advanced biologics manufacturing. Within this landscape, the viral vector manufacturing market and viral vector production market are seeing sustained demand as more therapies transition from clinical trials to commercialization, creating pressure on scalable, GMP-compliant capacity. At the same time, the viral vector and plasmid DNA manufacturing market is gaining strategic importance, as plasmid DNA remains a critical raw material for viral vector production, directly influencing yield, quality, and timelines. In parallel, while viral vectors dominate clinical pipelines, the non-viral vector industry is emerging as a complementary space, driven by interest in alternative delivery technologies that offer advantages in safety, repeat dosing, and manufacturing simplicity for certain applications.

From a business model perspective, the viral vector CDMO market has become a central pillar of industry growth, as biopharma companies increasingly outsource development and manufacturing to specialized partners to reduce capital risk and accelerate time to market. CDMOs are expanding capabilities across multiple vector types, integrating plasmid DNA supply, upstream and downstream processing, and analytical services to offer end-to-end solutions. In addition, the viral vector vaccines market continues to contribute to overall demand, supported by platform validation during recent global health initiatives and ongoing development of vaccines for infectious diseases and oncology indications. Together, these interconnected segments are shaping a dynamic and capital-intensive market, where capacity expansion, technological innovation, and strategic partnerships remain critical to long-term growth.

Global Viral Vector Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global viral vector market based on vector type, application, end use, and region:

  • Vector Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Adeno-associated virus (AAV)
  • Adenovirus
  • Lentivirus
  • Retrovirus
  • Others
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Cell & Gene Therapy
  • Vaccine
  • Biopharmaceutical & Pharmaceutical Discovery
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmaceutical and Biotechnology Companies
  • Academics and Research Institutes
  • CROs & CMOs
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Vector Type
    • 1.2.2. Application
    • 1.2.3. End use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives
    • 1.10.1. Objective 1
    • 1.10.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends and Outlook
  • 3.4. Market Dynamics
    • 3.4.1. Increasing demand for gene therapies
    • 3.4.2. Rising investments in research and development with immense funding support
  • 3.5. Market Restraint Analysis
    • 3.5.1. Complex manufacturing process.
    • 3.5.2. Regulatory challenges and intellectual property issues.
  • 3.6. Business Environment Analysis
    • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.6.2. Porter's Five Forces Analysis

Chapter 4. Viral Vector Market: Vector Type Size Estimated & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Viral vector market: Vector Type Movement Analysis
  • 4.3. Adeno-associated virus (AAV)
    • 4.3.1. Adeno-associated virus (AAV) Market, 2021 - 2033 (USD Million)
  • 4.4. Adenovirus
    • 4.4.1. Adenovirus Market, 2021 - 2033 (USD Million)
  • 4.5. Lentivirus
    • 4.5.1. Lentivirus Market, 2021 - 2033 (USD Million)
  • 4.6. Retrovirus
    • 4.6.1. Retrovirus Market, 2021 - 2033 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Viral Vector Market: Application Size Estimated & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Viral vector market: Application Movement Analysis
  • 5.3. Cell and Gene Therapy
    • 5.3.1. Cell and Gene Therapy Market, 2021 - 2033 (USD Million)
  • 5.4. Vaccine
    • 5.4.1. Vaccine Market, 2021 - 2033 (USD Million)
  • 5.5. Biopharmaceutical & Pharmaceuticals Discovery
    • 5.5.1. Biopharmaceutical & Pharmaceuticals Discovery Market, 2021 - 2033 (USD Million)

Chapter 6. Viral Vector Market: End Use Size Estimated & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Viral vector market: End Use Movement Analysis
  • 6.3. Pharmaceutical and Biotechnology Companies
    • 6.3.1. Pharmaceutical and Biotechnology Companies Market, 2021 - 2033 (USD Million)
  • 6.4. Academic and Research Institutes
    • 6.4.1. Academic and Research Institutes Market, 2021 - 2033 (USD Million)
  • 6.5. CROs & CMOs
    • 6.5.1. CROs and CMOs Market, 2021 - 2033 (USD Million)

Chapter 7. Viral Vector Market: Regional Size Estimated & Trend Analysis

  • 7.1. Viral Vector Market Share by Region, 2025 & 2033
  • 7.2. North America
    • 7.2.1. North America Viral vector market, 2021 - 2033 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. Competitive Scenario
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. U.S. viral vector market, 2021 - 2033 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Competitive Scenario
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Canada Viral vector market, 2021 - 2033 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Key Country Dynamics
      • 7.2.4.2. Competitive Scenario
      • 7.2.4.3. Regulatory Framework
      • 7.2.4.4. Mexico Viral vector market, 2021 - 2033 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Viral vector market, 2021 - 2033 (USD Million)
    • 7.3.2. Germany
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. Germany Viral vector market, 2021 - 2033 (USD Million)
    • 7.3.3. UK
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. UK Viral vector market, 2021 - 2033 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Competitive Scenario
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. France Viral vector market, 2021 - 2033 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Competitive Scenario
      • 7.3.5.3. Regulatory Framework
      • 7.3.5.4. Italy Viral vector market, 2021 - 2033 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Competitive Scenario
      • 7.3.6.3. Regulatory Framework
      • 7.3.6.4. Spain Viral vector market, 2021 - 2033 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Competitive Scenario
      • 7.3.7.3. Regulatory Framework
      • 7.3.7.4. Denmark Viral vector market, 2021 - 2033 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Competitive Scenario
      • 7.3.8.3. Regulatory Framework
      • 7.3.8.4. Sweden Viral vector market, 2021 - 2033 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Competitive Scenario
      • 7.3.9.3. Regulatory Framework
      • 7.3.9.4. Norway Viral vector market, 2021 - 2033 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Viral vector market, 2021 - 2033 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Japan Viral vector market, 2021 - 2033 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. China Viral vector market, 2021 - 2033 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. India Viral vector market, 2021 - 2033 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Competitive Scenario
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. South Korea Viral vector market, 2021 - 2033 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Competitive Scenario
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Australia Viral vector market, 2021 - 2033 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Competitive Scenario
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Thailand Viral vector market, 2021 - 2033 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Viral vector market, 2021 - 2033 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Brazil Viral vector market, 2021 - 2033 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Argentina Viral vector market, 2021 - 2033 (USD Million)
  • 7.6. MEA
    • 7.6.1. MEA Viral vector market, 2021 - 2033 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. South Africa Viral vector market, 2021 - 2033 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Saudi Arabia Viral vector market, 2021 - 2033 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. UAE Viral vector market, 2021 - 2033 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Kuwait Viral vector market, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Profiles/Listing
    • 8.3.1. Oxford Biomedica
      • 8.3.1.1. Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Product Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Thermo Fisher Scientific, Inc.
      • 8.3.2.1. Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Product Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. Lonza.
      • 8.3.3.1. Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Product Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Batavia Biosciences B.V.
      • 8.3.4.1. Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Product Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. Biogen
      • 8.3.5.1. Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Product Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Asklepios BioPharmaceutical, Inc. (AskBio)
      • 8.3.6.1. Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Product Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. Sanofi
      • 8.3.7.1. Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Product Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. Spark Therapeutics, Inc.
      • 8.3.8.1. Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Product Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Regenxbio Inc.
      • 8.3.9.1. Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Product Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. uniQURE N.V.
      • 8.3.10.1. Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Product Benchmarking
      • 8.3.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 Global viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 3 Global viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 4 Global viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 5 Global viral vector market, by region, 2021 - 2033 (USD Million)
  • Table 6 North America viral vector market, by country, 2021 - 2033 (USD Million)
  • Table 7 North America viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 8 North America viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 9 North America viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 10 U.S. viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 11 U.S. viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 12 U.S. viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 13 Canada viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 14 Canada viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 15 Canada viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 16 Mexico viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 17 Mexico viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 18 Mexico viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 19 Europe viral vector market, by country, 2021 - 2033 (USD Million)
  • Table 20 Europe viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 21 Europe viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 22 Europe viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 23 Germany viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 24 Germany viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 25 Germany viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 26 UK viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 27 UK viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 28 UK viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 29 France viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 30 France viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 31 France viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 32 Italy viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 33 Italy viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 34 Italy viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 35 Spain viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 36 Spain viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 37 Spain viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 38 Denmark viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 39 Denmark viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 40 Denmark viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 41 Sweden viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 42 Sweden viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 43 Sweden viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 44 Norway viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 45 Norway viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 46 Norway viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 47 Asia Pacific viral vector market, by country, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 51 China viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 52 China viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 53 China viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 54 Japan viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 55 Japan viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 56 Japan viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 57 India viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 58 India viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 59 India viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 60 South Korea viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 61 South Korea viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 62 South Korea viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 63 Australia viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 64 Australia viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 65 Australia viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 66 Thailand viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 67 Thailand viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 68 Thailand viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 69 Latin America viral vector market, by country, 2021 - 2033 (USD Million)
  • Table 70 Latin America viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 71 Latin America viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 72 Latin America viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 73 Brazil viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 74 Brazil viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 75 Brazil viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 76 Argentina viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 77 Argentina viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 78 Argentina viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 79 Middle East & Africa viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 80 Middle East & Africa viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 81 Middle East & Africa viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 82 South Africa viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 83 South Africa viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 84 South Africa viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 85 Saudi Arabia viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 86 Saudi Arabia viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 88 UAE viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 89 UAE viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 90 UAE viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 91 Kuwait viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 92 Kuwait viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 93 Kuwait viral vector market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 Viral vector market segmentation
  • Fig. 8 Market snapshot, 2025
  • Fig. 9 Market trends & outlook
  • Fig. 10 Market driver relevance analysis (current & future impact)
  • Fig. 11 Market restraint relevance analysis (current & future impact)
  • Fig. 12 Swot analysis, by factor (political & legal, economic and technological)
  • Fig. 13 Porter's five forces analysis
  • Fig. 14 Global viral vector market: vector type movement analysis
  • Fig. 15 Global viral vector market, for adeno-associated virus (AAV), 2021 - 2033 (USD Million)
  • Fig. 16 Global viral vector market, for adenovirus, 2021 - 2033 (USD Million)
  • Fig. 17 Global viral vector market, for lentivirus, 2021 - 2033 (USD Million)
  • Fig. 18 Global viral vector market, for retrovirus, 2021 - 2033 (USD Million)
  • Fig. 19 Global viral vector market, for others, 2021 - 2033 (USD Million)
  • Fig. 20 Global viral vector market: application movement analysis
  • Fig. 21 Global viral vector market, for cell & gene therapy, 2021 - 2033 (USD Million)
  • Fig. 22 Global viral vector market, for vaccine, 2021 - 2033 (USD Million)
  • Fig. 23 Global viral vector market, for biopharmaceutical and pharmaceutical discovery, 2021 - 2033 (USD Million)
  • Fig. 24 Global viral vector market: End use movement analysis
  • Fig. 25 Global viral vector market, for pharmaceutical and biotechnology companies, 2021 - 2033 (USD Million)
  • Fig. 26 Global viral vector market, for academic and research institutes, 2021 - 2033 (USD Million)
  • Fig. 27 Global viral vector market, for CROs and CMOs, 2021 - 2033 (USD Million)
  • Fig. 28 Regional marketplace: key takeaways
  • Fig. 29 Regional outlook, 2025 & 2033
  • Fig. 30 Global viral vector market: region movement analysis
  • Fig. 31 North America viral vector market, 2021 - 2033 (USD Million)
  • Fig. 32 U.S. Viral vector market, 2021 - 2033 (USD Million)
  • Fig. 33 Canada viral vector market, 2021 - 2033 (USD Million)
  • Fig. 34 Mexico viral vector market, 2021 - 2033 (USD Million)
  • Fig. 35 Europe viral vector market, 2021 - 2033 (USD Million)
  • Fig. 36 Germany viral vector market, 2021 - 2033 (USD Million)
  • Fig. 37 UK viral vector market, 2021 - 2033 (USD Million)
  • Fig. 38 France viral vector market, 2021 - 2033 (USD Million)
  • Fig. 39 Italy viral vector market, 2021 - 2033 (USD Million)
  • Fig. 40 Spain viral vector market, 2021 - 2033 (USD Million)
  • Fig. 41 Denmark viral vector market, 2021 - 2033 (USD Million)
  • Fig. 42 Sweden viral vector market, 2021 - 2033 (USD Million)
  • Fig. 43 Norway viral vector market, 2021 - 2033 (USD Million)
  • Fig. 44 Asia pacific viral vector market, 2021 - 2033 (USD Million)
  • Fig. 45 Japan viral vector market, 2021 - 2033 (USD Million)
  • Fig. 46 China viral vector market, 2021 - 2033 (USD Million)
  • Fig. 47 India viral vector market, 2021 - 2033 (USD Million)
  • Fig. 48 Australia viral vector market, 2021 - 2033 (USD Million)
  • Fig. 49 South Korea viral vector market, 2021 - 2033 (USD Million)
  • Fig. 50 Thailand viral vector market, 2021 - 2033 (USD Million)
  • Fig. 51 Latin America viral vector market, 2021 - 2033 (USD Million)
  • Fig. 52 Brazil viral vector market, 2021 - 2033 (USD Million)
  • Fig. 53 Argentina viral vector market, 2021 - 2033 (USD Million)
  • Fig. 54 Middle East and Africa viral vector market, 2021 - 2033 (USD Million)
  • Fig. 55 South Africa viral vector market, 2021 - 2033 (USD Million)
  • Fig. 56 Saudi Arabia viral vector market, 2021 - 2033 (USD Million)
  • Fig. 57 UAE viral vector market, 2021 - 2033 (USD million
  • Fig. 58 Kuwait viral vector market, 2021 - 2033 (USD Million)